THALES
7.10.2019 07:47:05 CEST | Business Wire | Press release
Powered by the cutting-edge technologies and products of Thales and Verint, the two companies are pleased to present The Cyberthreat Handbook , a report of unprecedented scope designed to provide a classification and basis for further investigation of major groups of cyberattackers, including cybercriminals, cyberterrorists, hacktivist groups and state-sponsored hackers. As part of the strategic partnership to create a comprehensive, state-of-the art Cyber Threat Intelligence technologies, threat intelligence analysts from Thales and Verint have worked together to provide this unique 360° view of the cyberthreat landscape, with detailed descriptions of the activities of about sixty particularly significant groups, including their tactics and techniques, their motives and the sectors targeted from analysis of multiple data sources such as web and threat intelligence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191006005044/en/
As cybersecurity grows in importance, Thales and Verint have worked together to find out more about cyberattackers and the techniques they employ, the purpose being to help organisations in the private and public sectors to better detect and anticipate future attacks. The cyberthreat landscape is extremely diversified, and knowing one's enemies can be particularly complex in this world of subterfuge and deception.
"The Thales and Verint teams are immensely proud to release this report today as part of its technology and domain expertise cooperation. Unique in its breadth and depth, it is the culmination of many months of research, investigation and painstaking analysis and correlation of relevant data. As cyberthreats proliferate and evolve, cybersecurity clearly has a major role to play, particularly for critical infrastructure providers. It is our duty to analyse, understand and describe the techniques employed by cyberattackers so that our customers and all other businesses and organisations are better prepared to detect and anticipate future attacks." Marc Darmon, Executive Vice President, Secure Communications and Information Systems, Thales
“Joining forces with Thales strengthens our mutual ability to deliver comprehensive knowledge of potential threats, and thus provide the necessary cyber security protection,” said Elad Sharon, President, Verint Cyber Intelligence Solutions. “Verint Cyber Intelligence leverages years of intelligence domain expertise, embedded within investigation methodologies and technologies critical to prevent cyber-attacks before they get into the gateway of the organization. This report generates unique insights and knowldege to cyber and security experts to mitigate and foresee cyberattacks”.
Analysts from Thales and Verint have defined four major categories of attackers based on their motives and ultimate objectives. Out of approximately sixty major groups of attackers analysed, 49% are state-sponsored groups often aiming to steal sensitive data from targets of geopolitical interest. 26% are ideologically motivated hacktivists, closely followed by cybercriminals (20%) who are driven by financial gain. In fourth position, cyberterrorists account for 5% of the groups analysed.
All the world's major economic, political and military powers are priority targets of cyberattackers. The 12 countries in the world with the highest GDP are all at the top of the list of targets, headed by the United States, Russia, the European Union (particularly the United Kingdom, France and Germany) and China, followed by India, South Korea and Japan.
The sectors most targeted by these major attacks are States and their defence capabilities, followed by the financial sector, energy and transportation. Attacks towards medias and health industry are increasing fast.
Last but not least, a growing number of groups of attackers are now focusing on vulnerabilities in the supply chain, and in particular on smaller partners, suppliers and service providers that are used as trojans to access major targets.
Notes to editors - Methodology This report does not set out to be an exhaustive inventory of cyberattackers but rather to shed light on the major groups of attackers that have been identified over the last 10 years. The sixty-odd groups and 490 attack campaigns analysed in the report were selected because they are considered emblematic in terms of their impact, attack techniques, scope, target profiles, historical nature or recent emergence. The entire analysis is based on the MITRE Att&ck matrix , a knowledge base of adversary tactics and techniques. More details can be found in the press kit.
About Thales Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 80,000 employees in 68 countries, Thales generated sales of €19 billion in 2018 (on a pro forma basis including Gemalto).
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments
About Verint Systems Inc. Verint® (Nasdaq: VRNT) is a global leader in Actionable Intelligence® solutions with a focus on customer engagement optimisation, security intelligence, and fraud, risk and compliance. Today, over 10,000 organisations in more than 180 countries—including over 80 percent of the Fortune 100—count on intelligence from Verint solutions to make more informed, effective and timely decisions. Learn more about how we’re creating A Smarter World with Actionable Intelligence® at www.verint.com .
About Verint Cyber Intelligence. Verint Cyber Intelligence is a leading global provider of security and intelligence data mining software. Our broad and deep product portfolio is deployed in over 100 countries, helping government, critical infrastructure and enterprise organizations to neutralize and prevent terror, crime and cyber threats for a safer world. |
PLEASE VISIT
Thales Group
Download photos
Download the report
View source version on businesswire.com: https://www.businesswire.com/news/home/20191006005044/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
